Meridian Bioscience
Market Cap
US$426.7m
Last Updated
2019/09/16 23:38 UTC
Data Sources
Company Financials +
Executive Summary
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.
Snowflake
Fundamentals
Adequate balance sheet and fair value.
Similar Companies
Share Price & News
How has Meridian Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
5.2%
NasdaqGS:VIVO
0.8%
US Medical Equipment
1.1%
US Market
1 Year Return
-35.5%
NasdaqGS:VIVO
9.6%
US Medical Equipment
2.1%
US Market
VIVO underperformed the Medical Equipment industry which returned 9.1% over the past year.
VIVO underperformed the Market in United States of America which returned 2% over the past year.
Share holder returns
| VIVO | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.2% | 0.8% | 1.1% |
| 30 Day | -1.2% | 0.2% | 3.7% |
| 90 Day | -15.3% | 2.7% | 2.3% |
| 1 Year | -34.6%-35.5% | 10.5%9.6% | 4.4%2.1% |
| 3 Year | -43.5%-48.2% | 69.5%64.3% | 47.0%37.4% |
| 5 Year | -33.7%-44.3% | 132.5%105.9% | 61.6%43.8% |
Price Volatility Vs. Market
How volatile is Meridian Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Are Insiders Selling Meridian Bioscience, Inc. (NASDAQ:VIVO) Stock?4 weeks ago | Simply Wall St
Is Meridian Bioscience (NASDAQ:VIVO) A Risky Investment?1 month ago | Simply Wall St
Does Meridian Bioscience, Inc.'s (NASDAQ:VIVO) P/E Ratio Signal A Buying Opportunity?Valuation
Is Meridian Bioscience undervalued based on future cash flows and its price relative to the stock market?
16.51x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Meridian Bioscience's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Meridian Bioscience's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Meridian Bioscience is good value based on earnings compared to the US Medical Equipment industry average.
Meridian Bioscience is good value based on earnings compared to the United States of America market.
Price Based on Expected Growth
Meridian Bioscience earnings are not expected to grow next year, we can't assess if its growth is good value.
Price Based on Value of Assets
Meridian Bioscience is good value based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Meridian Bioscience expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
-0.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Meridian Bioscience's revenue is expected to grow by 1.8% yearly, however this is not considered high growth (20% yearly).
Meridian Bioscience's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
Meridian Bioscience's revenue growth is positive but not above the United States of America market average.
Meridian Bioscience's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Meridian Bioscience's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Meridian Bioscience is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Meridian Bioscience performed over the past 5 years?
-10.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Meridian Bioscience's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
Meridian Bioscience's 1-year earnings growth exceeds its 5-year average (6.5% vs -10.7%)
Meridian Bioscience's earnings growth has not exceeded the US Medical Equipment industry average in the past year (6.5% vs 28.9%).
Return on Equity
Meridian Bioscience has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Meridian Bioscience used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
Return on Capital Employed
Meridian Bioscience's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Meridian Bioscience's financial position?
Financial Position Analysis
Meridian Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Meridian Bioscience's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Meridian Bioscience's level of debt (40.2%) compared to net worth is high (greater than 40%).
Unable to establish if Meridian Bioscience's debt level has increased without past 5-year debt data.
Debt is well covered by operating cash flow (52.2%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 51.6x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1.8x debt.
Next Steps
Dividend
What is Meridian Bioscience's current dividend yield, its reliability and sustainability?
0.63%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Unable to evaluate Meridian Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Meridian Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Meridian Bioscience has not reported any payouts.
Unable to verify if Meridian Bioscience's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Meridian Bioscience has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Meridian Bioscience's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Meridian Bioscience's salary, the management and board of directors tenure and is there insider trading?
0.8yrs
Average management tenure
CEO
Jack Kenny (50yo)
1.9yrs
Tenure
US$1,872,166
Compensation
Mr. John P. Kenny, also known as Jack, has been the Chief Executive Officer of Meridian Bioscience, Inc. since October 9, 2017 and its Executive Vice President of the Diagnostics Business Unit since March ...
CEO Compensation Analysis
Jack's remuneration is about average for companies of similar size in United States of America.
Insufficient data for Jack to compare compensation growth.
Management Age and Tenure
0.8yrs
Average Tenure
56yo
Average Age
The average tenure for the Meridian Bioscience management team is less than 2 years, this suggests a new team.
Board Age and Tenure
2.7yrs
Average Tenure
65yo
Average Age
The average tenure for the Meridian Bioscience board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,000 |
| Max Price | US$11.26 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 5,000 |
| Max Price | US$11.37 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board & Lead Independent Director |
| Shares | 5,000 |
| Max Price | US$11.40 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 20,000 |
| Max Price | US$11.49 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 566 |
| Max Price | US$19.62 |
| Entity | Individual |
| Shares | 35,101 |
| Max Price | US$19.55 |
Ownership Breakdown
Management Team
Susan Rolih (70yo)
Consultant
- Tenure: 0.8yrs
- Compensation: US$626.75k
Melissa Lueke (56yo)
Consultant
- Tenure: 0.7yrs
- Compensation: US$629.27k
Bryan Baldasare
Interim CFO
- Tenure: 0.3yrs
Lourdes Weltzien
Executive Vice President of Life Science Business Unit
- Tenure: 6yrs
Jack Kenny (50yo)
President
- Tenure: 1.9yrs
- Compensation: US$1.87m
Melissa McCarey
Vice President of Global Human Resources
- Tenure: 0yrs
Board Members
John Rice (69yo)
Independent Director
- Tenure: 2.1yrs
- Compensation: US$92.54k
John McIlwraith (60yo)
Independent Director
- Tenure: 4.1yrs
- Compensation: US$93.79k
David Phillips (81yo)
Chairman of the Board & Lead Independent Director
- Tenure: 1yrs
- Compensation: US$128.79k
James Anderson (77yo)
Independent Director
- Tenure: 10.2yrs
- Compensation: US$110.79k
Felicia Williams (53yo)
Director
- Tenure: 1yrs
- Compensation: US$41.11k
Dee Ellingwood (67yo)
Independent Director
- Tenure: 5.2yrs
- Compensation: US$95.79k
Catherine Sazdanoff (63yo)
Independent Director
- Tenure: 4.1yrs
- Compensation: US$92.79k
Jack Kenny (50yo)
President
- Tenure: 1.9yrs
- Compensation: US$1.87m
Dave Phillips
- Tenure: 0.8yrs
Company Information
Meridian Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Meridian Bioscience, Inc.
- Ticker: VIVO
- Exchange: NasdaqGS
- Founded: 1976
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$426.688m
- Shares outstanding: 42.71m
- Website: https://www.meridianbioscience.com
Number of Employees
Location
- Meridian Bioscience, Inc.
- 3471 River Hills Drive
- Cincinnati
- Ohio
- 45244
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| VIVO | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Jul 1986 |
| MR4 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jul 1986 |
| 0K0K | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Jul 1986 |
Biography
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevat ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/16 23:38 |
| End of Day Share Price | 2019/09/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.